Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 2Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Leukemia, Myeloid, Chronic-Phase 4Burkitt Lymphoma 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Lymphoma 2Leukemia 2Hematologic Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Substance Withdrawal Syndrome 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Ovarian Neoplasms 1Neoplasms 1Neoplasm, Residual 1Multiple Myeloma 1Melanoma 1Lung Neoplasms 1Leukemia, Biphenotypic, Acute 1Glioma 1Frailty 1Esophageal Neoplasms 1Endometrial Neoplasms 1

Interventions

pembrolizumab 46Cisplatin 31Carboplatin 20Cetuximab 16Nivolumab 15Paclitaxel 14Radiotherapy, Intensity-Modulated 12Radiotherapy 10Docetaxel 10Fluorouracil 9Platinum 8durvalumab 7Taxes 71,2-diaminocyclohexaneplatinum II citrate 7Radiation 6tislelizumab 5Magnetic Resonance Spectroscopy 5Albumin-Bound Paclitaxel 5cemiplimab 4avelumab 4Specimen Handling 4Radiosurgery 4Drug Therapy 4Biopsy 4130-nm albumin-bound paclitaxel 4tremelimumab 3palbociclib 3olaparib 3dostarlimab 3atezolizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Squamous Cell Carcinoma of Head and Neck × Dasatinib × Clear all
NCT05724329 2024-09-19

Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Active not recruiting
24 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon âš¡